Veracyte Inc reports results for the quarter ended December 31 - Earnings Summary

• Veracyte Inc VCYT.OQ reported quarterly adjusted earnings of 6 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -39 cents. The mean expectation of twelve analysts for the quarter was for earnings of 11 cents per share. Wall Street expected results to range from 5 cents to 15 cents per share.

• Revenue rose 20.8% to $118.63 million from a year ago; analysts expected $116.77 million.

• Veracyte Inc's reported EPS for the quarter was 6 cents​.

• The company reported quarterly net income of $5.11 million.

• Veracyte Inc shares had fallen by 1.1% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," 2 "hold" and 1 "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Veracyte Inc is $48.00

This summary was machine generated from LSEG data February 24 at 10:41 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)